File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1681/ASN.2013010103
- Scopus: eid_2-s2.0-84891774529
- WOS: WOS:000329155800020
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Effect of paricalcitol on left ventricular mass and function in CKD-The OPERA trial
Title | Effect of paricalcitol on left ventricular mass and function in CKD-The OPERA trial |
---|---|
Authors | |
Issue Date | 2014 |
Citation | Journal of the American Society of Nephrology, 2014, v. 25, n. 1, p. 175-186 How to Cite? |
Abstract | Vitamin D seems to protect against cardiovascular disease, but the reported effects of vitaminDon patient outcomes in CKD are controversial. We conducted a prospective, double blind, randomized, placebocontrolled trial to determine whether oral activated vitamin D reduces left ventricular (LV)mass in patients with stages 3-5 CKD with LV hypertrophy. Subjects with echocardiographic criteria of LV hypertrophy were randomly assigned to receive either oral paricalcitol (1 μg) one time daily (n=30) ormatching placebo (n=30) for 52 weeks. The primary end point was change in LV mass index over 52 weeks, which was measured by cardiac magnetic resonance imaging. Secondary end points included changes in LV volume, echocardiographic measures of systolic and diastolic function, biochemical parameters of mineral bone disease, and measures of renal function. Change in LV mass index did not differ significantly between groups (median [interquartile range], 22.59 [26.13 to 0.32] g/m2 with paricalcitol versus 24.85 [29.89 to 1.10] g/m2 with placebo). Changes in LV volume, ejection fraction, tissue Doppler-derived measures of early diastolic and systolicmitral annular velocities, and ratio of earlymitral inflowvelocity to early diastolic mitral annular velocity did not differ between the groups. However, paricalcitol treatment significantly reduced intact parathyroid hormone (P,0.001) and alkaline phosphatase (P=0.001) levels as well as the number of cardiovascular-related hospitalizations compared with placebo. In conclusion, 52 weeks of treatment with oral paricalcitol (1 mg one time daily) significantly improved secondary hyperparathyroidism but did not alter measures of LV structure and function in patients with severe CKD. Copyright © 2014 by the American Society of Nephrology. |
Persistent Identifier | http://hdl.handle.net/10722/228477 |
ISSN | 2021 Impact Factor: 14.978 2020 SCImago Journal Rankings: 4.451 |
ISI Accession Number ID |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Wang, Angela Yee Moon | - |
dc.contributor.author | Fang, Fang | - |
dc.contributor.author | Chan, John | - |
dc.contributor.author | Wen, Yue Yi | - |
dc.contributor.author | Qing, Shang | - |
dc.contributor.author | Chan, Iris Hiu Shuen | - |
dc.contributor.author | Lo, Gladys | - |
dc.contributor.author | Lai, Kar Neng | - |
dc.contributor.author | Lo, Wai Kei | - |
dc.contributor.author | Lam, Christopher Wai Kei | - |
dc.contributor.author | Yu, Cheuk Man | - |
dc.date.accessioned | 2016-08-13T08:02:30Z | - |
dc.date.available | 2016-08-13T08:02:30Z | - |
dc.date.issued | 2014 | - |
dc.identifier.citation | Journal of the American Society of Nephrology, 2014, v. 25, n. 1, p. 175-186 | - |
dc.identifier.issn | 1046-6673 | - |
dc.identifier.uri | http://hdl.handle.net/10722/228477 | - |
dc.description.abstract | Vitamin D seems to protect against cardiovascular disease, but the reported effects of vitaminDon patient outcomes in CKD are controversial. We conducted a prospective, double blind, randomized, placebocontrolled trial to determine whether oral activated vitamin D reduces left ventricular (LV)mass in patients with stages 3-5 CKD with LV hypertrophy. Subjects with echocardiographic criteria of LV hypertrophy were randomly assigned to receive either oral paricalcitol (1 μg) one time daily (n=30) ormatching placebo (n=30) for 52 weeks. The primary end point was change in LV mass index over 52 weeks, which was measured by cardiac magnetic resonance imaging. Secondary end points included changes in LV volume, echocardiographic measures of systolic and diastolic function, biochemical parameters of mineral bone disease, and measures of renal function. Change in LV mass index did not differ significantly between groups (median [interquartile range], 22.59 [26.13 to 0.32] g/m2 with paricalcitol versus 24.85 [29.89 to 1.10] g/m2 with placebo). Changes in LV volume, ejection fraction, tissue Doppler-derived measures of early diastolic and systolicmitral annular velocities, and ratio of earlymitral inflowvelocity to early diastolic mitral annular velocity did not differ between the groups. However, paricalcitol treatment significantly reduced intact parathyroid hormone (P,0.001) and alkaline phosphatase (P=0.001) levels as well as the number of cardiovascular-related hospitalizations compared with placebo. In conclusion, 52 weeks of treatment with oral paricalcitol (1 mg one time daily) significantly improved secondary hyperparathyroidism but did not alter measures of LV structure and function in patients with severe CKD. Copyright © 2014 by the American Society of Nephrology. | - |
dc.language | eng | - |
dc.relation.ispartof | Journal of the American Society of Nephrology | - |
dc.title | Effect of paricalcitol on left ventricular mass and function in CKD-The OPERA trial | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1681/ASN.2013010103 | - |
dc.identifier.scopus | eid_2-s2.0-84891774529 | - |
dc.identifier.volume | 25 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 175 | - |
dc.identifier.epage | 186 | - |
dc.identifier.eissn | 1533-3450 | - |
dc.identifier.isi | WOS:000329155800020 | - |
dc.identifier.issnl | 1046-6673 | - |